Jefferies Maintains Immunocore(IMCR.US) With Buy Rating, Cuts Target Price to $45

Futu NewsDec 21 02:31 · Ratings

Immunocore Begins Phase 1/2 Trial of IMC-R117C, The First Immunotherapy Targeting PIWIL1 In Advanced Gastrointestinal Cancers

BenzingaDec 17 20:05

Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry?

Simply Wall StDec 14 21:41

Morgan Stanley Upgrades PTC, Cuts Immuneering, Amicus

Seeking AlphaDec 14 03:42

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

BenzingaDec 14 03:10

Immunocore Holdings Cut to Equal-Weight From Overweight by Morgan Stanley

Dow JonesDec 13 20:11 · Ratings